Prostate Cancer

Insight from Urologist David Morris, MD, FACS, as he reacts to the educational video from AbbVie on cardiovascular risk and androgen deprivation therapy.

Cardiologist Anees A. Daud, MD, highlights how a cardiologist may followup with patients receiving androgen deprivation therapy and how multidisciplinary care plays a role in this setting.

David Morris, MD, FACS, shares advice on followup with patients on androgen deprivation therapy for prostate cancer.

All patients with platinum-resistant, small-cell neuroendocrine prostate cancer who responded to treatment with BXCL701 plus pembrolizumab were microsatellite stable and/or tumor mutational burden–low with a low probability of response to pembrolizumab.

Data from a phase 2 placebo-controlled trial may support darolutamide switch maintenance therapy following at least 1 androgen receptor pathway inhibitor and taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.

Investigators report that pembrolizumab plus enzalutamide and androgen deprivation therapy does not significantly improve outcomes in castration-resistant prostate cancer; neither did pembrolizumab/chemotherapy in non–small cell lung cancer.

Expert insight on selection of androgen deprivation therapy and how related adverse events may be communicated to patients in advance.

Urologist David Morris, MD, FACS, shares his perspective on communicating cardiovascular risk to patients starting androgen deprivation therapy.

Joelle Hamilton, MD, reflects on strategies used in oncology practice to mitigate cardiovascular risk in patients with prostate cancer.

Insight is provided on strategies that may be employed to mitigate cardiovascular risk in patients receiving care for prostate cancer.

Patients with BRCA-positive metastatic castration-resistant prostate cancer may benefit from treatment with niraparib plus dual action abiraterone acetate tablets and prednisone, a new drug application for which was submitted to the FDA.

Expert perspectives on the typical patient workup that occurs in oncology practice to identify cardiovascular risk.

Rucaparib yields improved efficacy compared with docetaxel plus androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer harboring BRCA mutations.

Investigators observe low rates of treatment discontinuation and adverse effects with radium-223 as treatment for castration-resistant prostate cancer and bone metastases.

Niraparib plus abiraterone and prednisone continue to improve outcomes among patients with metastatic, castration-resistant prostate cancer and HRR gene alterations, according to interim data from the MAGNITUDE study.

Long-term safety data from the phase 3 ARAMIS rollover trial support the use of darolutamide in patients with nonmetastatic castration-resistant prostate cancer, according to an expert from the Carolina Urologic Research Center.

In a final overall survival analysis of the phase 3 PROpel study, abiraterone actetate/olaparib demonstrates a sustained trend toward overall survival for metastatic castration-resistant prostate cancer vs standard-of-care abiraterone.

Findings from the phase 3 ARASENS trial indicate that darolutamide plus androgen-deprivation therapy and docetaxel should be considered a new standard of care for metastatic hormone-sensitive prostate cancer.

Treatment with talazoparib and enzalutamide appears to yield a statistically significant and clinically meaningful radiographic progression-free survival benefit compared with placebo/enzalutamide in frontline metastatic castration-resistant prostate cancer regardless of homologous recombination repair status.

Expert perspectives on the risk of cardiovascular disease as it exists in the context of androgen deprivation therapy (ADT) and prostate cancer.

Treatment with 177Lu-PSMA-617 results in similar survival benefit regardless of when it was administered after radium-223 in patients with metastatic castration-resistant prostate cancer, according to an expert from University Hospital of Münster in Germany.

Darolutamide produces a lower rate of discontinuation compared with enzalutamide or apalutamide among patients with non-metastatic, castration-resistant prostate cancer.

Early study results show that an artificial intelligence model may help oncologists better stratify patients with prostate cancer into risk groups than existing methods, according to an expert.

During the 2022 Society for Urologic Oncology (SUO) Annual Meeting, an expert from the Baylor College of Medicine, discussed how perceptions around the use of testosterone therapy have evolved for patients with metastatic prostate cancer.

Adding the investigational oral drug BXCL701 to pembrolizumab appears effective in small cell neuroendocrine metastatic castration-resistant prostate cancer, a rare and aggressive disease.